- Price
- $34.93
- Day
- +1.51%
- Mkt Cap
- $25.23B
- 52W Range
- $12.55 – $37.97
- Volume
- 5.24M
- Beta
- 1.12
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Roivant will also host an investor call and webcast at 8:00 a.m. ET on Tuesday, September 8, 2026.
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension.
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch.
Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month
Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a 30-day supply of their newly approved rare disease drug, Lisraya.